TITLE:
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

CONDITION:
Breast Neoplasms

INTERVENTION:
Tamoxifen

SUMMARY:

      To compare the sequential administration of exemestane with administration of further
      tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already
      received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall
      survival (OS), incidence of contralateral breast cancer and long-term tolerability.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 30 Years to N/A
Criteria:

        Inclusion Criteria:

          -  postmenopausal women with histologically or cytologically confirmed primary breast
             adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously
             for between 2 and 3 years and one month, and still free of disease

        Exclusion Criteria:

          -  unresectable breast cancer

          -  ER negative primary tumor
      
